about
Cytokines as new treatment targets in chronic heart failureInterleukin-7-mediated inflammation in unstable angina: possible role of chemokines and plateletsIncreased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammationIncreased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failurePrognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure.Peripheral endothelial dysfunction in heart transplant recipients: possible role of proinflammatory cytokines.The effect of rosuvastatin on inflammation, matrix turnover and left ventricular remodeling in dilated cardiomyopathy: a randomized, controlled trial.Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients.Exercise capacity in heart transplant recipients: relation to impaired endothelium-dependent vasodilation of the peripheral microcirculation.Effect of heart transplantation on impaired peripheral microvascular perfusion and reactivity in congestive heart failure.Endothelium-dependent vasodilation of the skin microcirculation in heart transplant recipients.Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes.Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF).Reproducibility of an extensive self-report questionnaire used in secondary coronary preventionConcomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis.Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathyMorbidity outcomes after surgical aortic valve replacement.Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overloadEffects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.The magnesium loading test: reference values in healthy subjects.The peripheral blood mononuclear cell microRNA signature of coronary artery disease.Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus.The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure.Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Increased levels of inflammatory cytokines and endothelin-1 in alveolar macrophages from patients with chronic heart failure.The homeostatic chemokine CCL21 predicts mortality in aortic stenosis patients and modulates left ventricular remodeling.CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials.Association of ficolin-3 with severity and outcome of chronic heart failure.Rosuvastatin in older patients with systolic heart failure.Increased systemic and local interleukin 9 levels in patients with carotid and coronary atherosclerosisLeft ventricular global longitudinal strain is associated with exercise capacity in failing hearts with preserved and reduced ejection fraction.The cytokine network in heart failure: pathogenetic importance and potential therapeutic targets.Immunomodulating therapy: new treatment modality in congestive heart failure.Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure.CXCR4 blockade induces atherosclerosis by affecting neutrophil functionSecreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin.Krill oil attenuates left ventricular dilatation after myocardial infarction in rats.Therapeutic potential of anticytokine therapy in congestive heart failure.
P50
Q24799394-ECF2A6B3-6887-4561-B13B-5ECC637E1380Q28195974-0A07B3DE-041F-40CF-9C67-E914C151D09FQ28200764-5391447F-3D13-44C2-A866-0A460F0ED63BQ28575465-43837951-6D22-46D2-B0A9-A6C2ED460FE4Q30587543-6D366783-DCF8-4EDD-98A7-A60FD1629A22Q30611192-2670B95F-7A31-47E5-B83B-7AC204164D70Q30873807-7975D5B4-CB99-4511-8EE6-1266DE81FD09Q31152172-7D7144D0-1515-47F9-826A-2C0EB4890331Q32023336-029EFA69-E24A-47E8-9FE1-6F12DCD611E7Q32038973-6268C256-C2A1-4ECC-89FB-40D0C6453CD8Q32040797-F0A73FAD-32B5-4E5B-929C-0BBE0F85BE63Q32047955-9CC4D041-2873-4291-9486-7635C3F96FD3Q32055041-4A6D9A2A-66FB-4AFA-BD9C-44C9C64FF802Q32083263-6AA33D0E-6E46-4BC1-9A9B-B3966A35DB43Q33605429-47F37576-8751-4FF3-8CE0-2BA0E1E534FEQ33725505-6F775BFC-CCFB-42A6-A81E-6D34BE418DA8Q33799421-0E0B2AE4-DDF3-4107-97D2-75C16D3A69B8Q33801871-D338A71B-78E7-4736-9D74-1AC8E6EAD172Q33886486-ECC99E2F-D825-4F0E-A508-9CD7153ACECCQ33893139-DDADE010-4270-4A3C-B920-5A13A3765EFFQ34060681-1459A872-8B94-450A-BF8A-4D6DE79D1BEAQ34104103-0A54B964-B263-489F-82C7-0558E8E71ED3Q34158074-0FBF9A84-C67C-4A6C-BB36-9F567297F774Q34200352-D9089234-6FD7-4233-8AA7-78136F135780Q34269132-FEB783F3-F314-45A8-9B11-A34793B38C69Q34277432-5890F074-CC6E-479A-B432-8BDCADD98CECQ34513415-4F8C095E-9F6D-4786-A7E3-C22553FC0ABBQ34619812-2AF4D08E-2518-47D4-A85C-EFCEF6E7B190Q34676160-C20AE69E-1DE2-432C-9C25-52D794C02C57Q34710349-291CB685-C168-48EF-82B3-D5AB00BC925DQ34983608-126772D4-3C22-4572-8F4F-20A6D0F728EDQ35018132-B8E28CEE-F697-49BE-84EF-39AFB78BE5E0Q35084669-D522C7F6-59A4-4028-9338-0C32B34A8DA9Q35097101-8601D6BB-FA8B-4BED-8E6A-B8A7CE5D3310Q35406034-B55729BC-9ECC-46EC-8706-8684A2561540Q35565559-0FF64114-08C9-4307-8228-19C1B091E211Q35750462-82ECC369-A305-4B1D-AA20-B9F270FC00C4Q35756990-D2D19A48-947D-4303-9D84-AE6C0B3BA467Q35761506-D60F189D-4DC9-4AFD-9B97-E0DB9CDC8FFFQ35768272-514D54A2-57C8-4FAE-A1D8-3497F991B05E
P50
description
Noors onderzoeker
@nl
norsk kardiolog
@nb
researcher
@en
ricercatore
@it
taighdeoir
@ga
հետազոտող
@hy
name
Lars Gullestad
@ast
Lars Gullestad
@da
Lars Gullestad
@de
Lars Gullestad
@en
Lars Gullestad
@es
Lars Gullestad
@fr
Lars Gullestad
@ga
Lars Gullestad
@nb
Lars Gullestad
@nl
Lars Gullestad
@nn
type
label
Lars Gullestad
@ast
Lars Gullestad
@da
Lars Gullestad
@de
Lars Gullestad
@en
Lars Gullestad
@es
Lars Gullestad
@fr
Lars Gullestad
@ga
Lars Gullestad
@nb
Lars Gullestad
@nl
Lars Gullestad
@nn
prefLabel
Lars Gullestad
@ast
Lars Gullestad
@da
Lars Gullestad
@de
Lars Gullestad
@en
Lars Gullestad
@es
Lars Gullestad
@fr
Lars Gullestad
@ga
Lars Gullestad
@nb
Lars Gullestad
@nl
Lars Gullestad
@nn
P106
P21
P214
203149294084880520588
P2287
P27
P31
P496
0000-0002-5932-6641
P735
P7859
viaf-203149294084880520588